A promising approach for restoring redox balance in IBD is pharmacological targeting of two signaling pathways of major physiological importance: HIF-1α and NRF2/KEAP1, the critical orchestrators of hypoxia- and oxidative stress-induced cellular response, respectively. The gene discussed is NFE2L2; the disease is inflammatory bowel disease.